Mission Statement, Vision, & Core Values (2026) of Terumo Corporation.

From its founding in 1921 to its footprint in over 160 countries and regions, Terumo Corporation (4543.T) threads a century of medical innovation with a clear compass-its Group Mission of 'Contributing to Society through Healthcare'-while operating across the Cardiac and Vascular, Medical Care Solutions, and Blood and Cell Technologies divisions to deliver patient-centered solutions; the company's 2025 articulation of 'Our Promise' renews a focus on listening to patients and accelerating product and service development that improves outcomes, and its guiding principles-Respect, Integrity, Care, Quality, Creativity-shape behavior across a global workforce of associates who bring gemba-driven quality, creativity in life sciences and hospital solutions, and an unwavering commitment to safety and reliability.

Terumo Corporation (4543.T) Intro

• Founded: 1921 in Japan; global medical technology company focused on improving patient outcomes and advancing healthcare delivery.
• Global footprint: operations and sales in over 160 countries and regions; network of manufacturing sites, R&D centers, and regional offices.
• Organizational structure: main operating groups include the Cardiac and Vascular Company, Medical Care Solutions Company, and Blood and Cell Technologies Company.
• Workforce: a global team of associates (approximately 24,000-26,000 people) driving product development, manufacturing, clinical support, and commercial activities.

• To contribute to society through healthcare by providing high-quality, reliable medical products and services that enhance patients' quality of life.
• Patient-centered priority: decisions, R&D, and commercial strategies are aligned to measurable improvements in clinical outcomes and safety.
• Associate-driven execution: emphasize collaboration, continuous learning, and ethical conduct across global teams.

• To be a global leader in medical innovation that shapes the future of healthcare-combining device technologies, procedural solutions, and life-science capabilities.
• Focus areas: minimally invasive therapies, perioperative & acute care support, and blood & cell technologies enabling regenerative and transfusion medicine.
• Long-term growth orientation: expand higher-value product lines and services while increasing presence in emerging markets.

• Patients first - all initiatives are evaluated by benefit to patients and clinical effectiveness.
• Integrity and compliance - rigorous quality management, regulatory compliance, and ethical supply-chain practices.
• Innovation - sustained investment in R&D, clinical evidence generation, and partnerships with academia and industry.
• Teamwork - cross-functional collaboration among associates worldwide to deliver complex solutions.
• Sustainability - commitment to environmental stewardship, safe workplaces, and social contribution programs.

• R&D strategy: combination of in-house development, strategic acquisitions, and collaborations to accelerate product lifecycle from concept to clinical adoption.
• Investment focus: catheter and device technologies for cardiology and endovascular therapy, infusion systems for hospital care, and automated platforms for blood & cell processing.
• Clinical evidence: emphasis on post-market surveillance and clinical trials to demonstrate safety and comparative effectiveness.

• Clinical outcomes: device-specific safety/effectiveness endpoints, readmission and complication rates.
• Growth metrics: revenue by division and region, new product sales percentage, market share in key therapy areas.
• Quality & compliance: regulatory inspection results, product recall frequency, CAPA metrics.
• People & culture: associate engagement scores, global training hours, diversity measures.
• Sustainability KPIs: energy usage, waste reduction, and community health initiatives.

• Terumo's mission and vision are embedded into business planning, capital allocation, and M&A criteria-prioritizing technologies that directly improve patient care.
• Associates are positioned as stewards of both clinical performance and corporate ethics, with incentive systems tied to quality and patient-outcome metrics.
• Public-facing transparency: annual reports and sustainability disclosures track progress on mission-driven targets and financial health.

Terumo Corporation (4543.T) - Overview

Terumo Corporation (4543.T) operates under a clear Group Mission: 'Contributing to Society through Healthcare.' This mission drives strategy, product development, and global operations, prioritizing patient outcomes, clinical value, and long-term societal benefit.

The mission is reflected across Terumo's businesses (Cardiac & Vascular, General Hospital, Blood Management) and shapes decisions from R&D prioritization to market expansion. Terumo's consistent mission focus supports sustainable growth, risk-managed investment, and alignment of corporate culture with stakeholder needs.

• Core mission statement: 'Contributing to Society through Healthcare.'
• Primary strategic goals: patient safety, clinician support, accessible therapies.
• Operational alignment: R&D investment, regulatory compliance, global manufacturing.

Mission-driven metrics (examples of how the mission translates to measurable actions):

• R&D intensity: sustained multi-year investment in product innovation and clinical evidence generation.
• Global footprint: manufacturing and sales presence across North America, Europe, Asia, and emerging markets to increase patient access.
• Quality & compliance: adherence to international medical device standards and continuous improvement programs.

Vision and Long-Term Direction

Terumo's vision centers on becoming a leading global healthcare company that delivers clinical value and societal benefit. This includes scaling minimally invasive therapies, expanding diagnostics and blood management capabilities, and leveraging digital health and data to improve care pathways.

• Strategic pillars: innovation in interventional technologies, strengthening hospital solutions, and expanding blood and cell therapy platforms.
• Growth focus: higher-margin product mix, emerging-market penetration, and selective M&A to complement organic R&D.
• Sustainability: integrating ESG into product design, supply chain resilience, and community health initiatives.

Core Values and Cultural Principles

Terumo's corporate culture is built around values that operationalize the mission:

• Patient-first mindset: safety and efficacy guide design and commercialization.
• Integrity and compliance: strict adherence to regulatory and ethical standards.
• Continuous innovation: iterative R&D and clinical collaboration with healthcare professionals.
• Global collaboration: cross-border teams and knowledge sharing to scale best practices.

Financial and Operational Context (Recent Indicators)

The following table provides representative, investor-relevant indicators that show how the mission and strategy map to financial performance and resourcing. Figures are illustrative of recent fiscal trends and Terumo's scale.

Key implications of these figures:

• Revenue scale enables sustained R&D and global clinical studies supporting the mission.
• Operating profitability funds strategic investments in higher-growth technologies (e.g., interventional devices, blood management).
• Workforce scale and geographic reach underpin rapid clinical adoption and post-market surveillance.

For investors and stakeholders seeking deeper context on shareholder composition and market positioning, see: Exploring Terumo Corporation Investor Profile: Who's Buying and Why?

Terumo Corporation (4543.T) - Mission Statement

• Our Promise (est. 2025): Reaffirms Terumo's long-term commitment to patients and to realizing the Group Mission.
• Patient focus: Prioritizes listening to patient needs and translating those insights into product and service innovations.
• Global impact: Commits to enhancing patients' quality of life worldwide, consistent with Terumo's historic healthcare mission.
• Growth orientation: Uses patient-centered vision as a driver for sustainable business growth and portfolio evolution.

• How the vision translates into actions:
  • Product development prioritizes unmet patient needs and clinician workflows.
  • Cross-segment initiatives to link devices, disposables, and digital solutions for better outcomes.
  • Metrics-driven goals: patient outcomes, access expansion, and responsible growth.
• Strategic alignment:
  • Leverages legacy strengths in vascular intervention, blood management, and infusion systems.
  • Uses M&A selectively to accelerate patient-impacting innovations and geographic reach.

Further background and historical context about Terumo's mission, ownership and how the company operates can be found here: Terumo Corporation: History, Ownership, Mission, How It Works & Makes Money

Terumo Corporation (4543.T) - Vision Statement

Terumo Corporation (4543.T) frames its vision and mission around improving patient outcomes worldwide by leveraging medical technology, global manufacturing, and partner networks. The company's strategic priorities align with its core values - Respect, Integrity, Care, Quality, and Creativity - which shape decision-making across R&D, manufacturing, clinical engagement, and commercial activities.

• Respect - Valuing associates, customers, and partners across cultures and geographies; promoting diversity and appreciation for individual contributions.
• Integrity - Acting with sincerity and a mission-driven mindset to build and maintain trust among stakeholders, regulators, and patients.
• Care - Keeping patients and clinicians central; designing processes and products with empathy and clinical understanding from the "gemba" (front line).
• Quality - Committing to safety, reliability, and continuous improvement; applying rigorous quality systems and viewing issues through on-site perspectives.
• Creativity - Encouraging innovation and challenge-oriented thinking to respond to front-line needs and deliver meaningful clinical and operational value.

These values are operationalized in clinical partnerships, product development pipelines, and corporate governance. Terumo's global footprint and financial scale provide context for how values translate into measurable activity:

Operationalizing values into measurable programs:

• Respect: Global HR initiatives for diversity & inclusion, cross-border training programs, and local community engagement in major manufacturing hubs.
• Integrity: Compliance frameworks, internal audits, and transparent reporting aligned with Japanese corporate governance codes and international regulations.
• Care: Clinician co-development programs, post-market surveillance, and customer-support models emphasizing frontline feedback.
• Quality: ISO-certified processes, site-level quality metrics, and continual gemba-driven corrective actions to reduce defect rates and enhance patient safety.
• Creativity: Investment in platform technologies, M&A to access novel modalities, and internal incubators to accelerate next-generation products.

Examples of value-driven outcomes include growth in minimally invasive therapy product lines (supporting higher-margin sales), expanded blood management solutions used in hospitals worldwide, and sustained R&D investment that feeds regulatory submissions and new market approvals.

Further background on Terumo's history, ownership and how the company creates value is available here: Terumo Corporation: History, Ownership, Mission, How It Works & Makes Money